The CXC chemokine MIG/CXCL9 is important in innate immunity against Streptococcus pyogenes

Journal of Infectious Diseases

Volumn 195, Issue 5, 2007, Pages 684-693

  Egesten, Arne ^a,d   Eliasson, Mette ^a   Johansson, Helena M ^a   Olin, Anders I ^a   Mörgelin, Matthias ^a   Mueller, Anja ^b,c   Pease, James E ^b   Frick, Inga Maria ^a   Björck, Lars ^a  

^a LUND UNIVERSITY   (Sweden)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^c UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^d BMC B14 ^*  (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA CHEMOKINE; BACTERIAL PROTEIN; CXCL11 CHEMOKINE; CXCL9 CHEMOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10;

ANTIBACTERIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; INFECTION RESISTANCE; INNATE IMMUNITY; NONHUMAN; PHARYNGITIS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SECRETION; SEROTYPE; STREPTOCOCCUS PYOGENES; TONSIL;

CELLS, CULTURED; CHEMOKINES, CXC; EPITHELIAL CELLS; GENE EXPRESSION REGULATION; HUMANS; IMMUNITY, NATURAL; PHARYNGITIS; PHARYNX; RECOMBINANT PROTEINS; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PYOGENES; TONSIL;

EID: 33847009078     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/510857     Document Type: Article

References (35)

1. Cunningham MW. Pathogenesis of group A streptococcal infections. Clin Microbiol Rev 2000; 13:470-511.
2. Lucey DR, Clerici M, Shearer GM. Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases. Clin Microbiol Rev 1996; 9:532-62.
3. Sansonetti PJ. War and peace at mucosal surfaces. Nat Rev Immunol 2004; 4:953-64.
4. Sauty A, Dziejman M, Taha RA, et al. The T cell-specific CXC chemokines IP-10, Mig, and I-TAC are expressed by activated human bronchial epithelial cells. J Immunol 1999; 162:3549-58.
5. Luster AD. The role of chemokines in linking innate and adaptive immunity. Curr Opin Immunol 2002; 14:129-35.
6. Liao F, Rabin RL, Yannelli JR, Koniaris LG, Vanguri P, Farber JM. Human Mig chemokine: biochemical and functional characterization. J Exp Med 1995; 182:1301-14.
7. Luster AD, Ravetch JV. Biochemical characterization of a gamma interferon-inducible cytokine (IP-10). J Exp Med 1987; 166:1084-97.
8. Cole KE, Strick CA, Paradis TJ, et al. Interferon-inducible T cell alpha chemoattractant (I-TAC): a novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3. J Exp Med 1998; 187:2009-21.
9. Loetscher M, Gerber B, Loetscher P, et al. Chemokine receptor specific for IP10 and Mig: structure, function, and expression in activated T-lymphocytes. J Exp Med 1996; 184:963-9.
10. Cole AM, Ganz T, Liese AM, Burdick MD, Liu L, Strieter RM. Cutting edge: IFN-inducible ELR-CXC chemokines display defensin-like antimicrobial activity. J Immunol 2001; 167:623-7.
11. Yang D, Chen Q, Hoover DM, et al. Many chemokines including CCL20/MIP-3 alpha display antimicrobial activity. J Leukoc Biol 2003; 74:448-55.
12. Fischetti VA. Streptococcal M protein: molecular design and biological behavior. Clin Microbiol Rev 1989; 2:285-314.
13. Musser JM, Krause RM. The revival of group A streptococcal diseases with a commentary on staphylococcal toxic shock syndrome. In: Krause R, ed. Emerging infections. New York: Academic Press, 1998:185-218.
14. Åkesson P, Sjöholm AG, Björck L. Protein SIC, a novel extracellular protein of Streptococcus pyogenes interfering with complement function. J Biol Chem 1996;271:1081-8.
15. Stockbauer KE, Grigsby D, Pan X, et al. Hypervariability generated by natural selection in an extracellular complement-inhibiting protein of serotype Ml strains of group A streptococcus. Proc Natl Acad Sci USA 1998;95:3128- 33.
16. Hoe NP, Nakashima K, Lukomski S, et al. Rapid selection of complement-inhibiting protein variants in group A streptococcus epidemic waves. Nat Med 1999; 5:924-9.
17. Fernie-King BA, Seilly DJ, Willers C, Wurzner R, Davies A, Lachmann PJ. Streptococcal inhibitor of complement (SIC) inhibits the membrane attack complex by preventing uptake of C567 onto cell membranes. Immunology 2001; 103:390-8.
18. Fernie-King BA, Seilly DJ, Davies A, Lachmann PJ. Streptococcal inhibitor of complement inhibits two additional components of the mucosal innate immune system: secretory leukocyte proteinase inhibitor and lysozyme. Infect Immun 2002; 70:4908-16.
19. Frick IM, Åkesson P, Rasmussen M, Schmidtchen A, Björck L. SIC, a secreted protein of Streptococcus pyogenes that inactivates antibacterial peptides. J Biol Chem 2003; 278:16561-6.
20. Xanthou G, Williams TJ, Pease JE. Molecular characterization of the chemokine receptor CXCR3: evidence for the involvement of distinct extracellular domains in a multi-step model of ligand binding and receptor activation. Eur J Immunol 2003; 33:2927-36.
21. Baschong W, Wrigley NG. Small colloidal gold conjugated to Fab fragments or to immunoglobulin G as high-resolution labels for electron microscopy: a technical overview. J Electron Microsc Tech 1990; 14:313-23.
22. Roth J, Bendayan M, Orci L. Ultrastructural localization of intracellular antigens by the use of protein A-gold complex. J Histochem Cytochem 1978; 26:1074-81.
23. Schwede T, Kopp J, Guex N, Peitsch MC. Swiss-model: an automated protein homology-modeling server. Nucleic Acids Res 2003; 31:3381-5.
24. Qian YQ, Johanson K, McDevitt P. Nuclear magnetic resonance solution structure of truncated human GRO-beta [5-73] and its structural comparison with CXC-chemokine family members GRO-alpha and IL-8. J Mol Biol 1999;294: 1065-72.
25. Kim DE, Chivian D, Baker D. Protein structure prediction and analysis using the Robetta server. Nucleic Acids Res 2004; 32:W526-31.
26. Andersson E, Rydengård V, Sonesson A, Mörgelin M, Björck L, Schmidtchen A. Antimicrobial activities of heparin-binding peptides. Eur J Biochem 2004; 271:1219-26.
27. Handel TM, Johnson Z, Crown SE, Lau EK, Proudfoot AE. Regulation of protein function by glycosaminoglycans as exemplified by chemokines. Annu Rev Biochem 2005; 74:385-410.
28. Aps JK, Martens LC. The physiology of saliva and transfer of drugs into saliva. Forensic Sci Int 2005; 150:119-31.
29. Swaminathan GJ, Holloway DE, Colvin RA, et al. Crystal structures of oligomeric forms of the IP-10/CXCL10 chemokine. Structure 2003; 11:521-32.
30. Booth V, Clark-Lewis I, Sykes BD. NMR structure of CXCR3 binding chemokine CXCL11 (ITAC). Protein Sci 2004; 13:2022-8.
31. Lukomski S, Hoe NP, Abdi I, et al. Nonpolar inactivation of the hypervariable Streptococcal inhibitor of complement gene (sic) in serotype M1 Streptococcus pyogenes significantly decreases mouse mucosal colonization. Infect Immun 2000; 68:535-42.
32. Hoe NP, Ireland RM, DeLeo FR, et al. Insight into the molecular basis of pathogen abundance: group A Streptococcus inhibitor of complement inhibits bacterial adherence and internalization into human cells. Proc Natl Acad Sci USA 2002; 99:7646-51.
33. Booth V, Keizer DW, Kamphuis MB, Clark-Lewis I, Sykes BD. The CXCR3 binding chemokine IP-10/CXCL10: structure and receptor interactions. Biochemistry 2002; 41:10418-25.
34. Campanella GS, Lee EM, Sun J, Luster AD. CXCR3 and heparin binding sites of the chemokine IP-10 (CXCL10). J Biol Chem 2003;278:17066-74.
35. LaPenta D, Rubens C, Chi E, Cleary PP. Group A streptococci efficiently invade human respiratory epithelial cells. Proc Natl Acad Sci USA 1994; 91:12115-9.